title: Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome.
abstract: We present the case of a woman with paranoid schizophrenia who was receiving oral risperidone. She developed neuroleptic malignant syndrome (NMS) following the addition of depot fluphenazine for the treatment of refractory delusions. NMS subsided and psychotic features were controlled after both antipsychotics were discontinued and the patient was treated instead with olanzapine.
authors.affiliation: Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.
authors.forename: Pang-Yen
authors.initials: PY
authors.lastname: Liu
authors.forename: Pei-Chuan
authors.initials: PC
authors.lastname: Wu
authors.forename: Chun-Yen
authors.initials: CY
authors.lastname: Chen
authors.forename: Yi-Chyan
authors.initials: YC
authors.lastname: Chen
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003702:Delusions / Q000188:drug therapy; D005260:Female; D005476:Fluphenazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D018967:Risperidone / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012563:Schizophrenia, Paranoid / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents; C011825:fluphenazine depot; D018967:Risperidone; D005476:Fluphenazine